← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
de Boer Daniel Anton
Chief Executive Officer | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0002117546
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 3
- Average purchase
- $284.5K
- Median purchase
- $261.0K
- Gross purchase value
- $853.5K
Companies: ProQR Therapeutics N.V.
3 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-03 | ProQR Therapeutics N.V. | PRQR | Chief Executive Officer | Officer | $354.0K | Open filing |
| 2026-07-13 | ProQR Therapeutics N.V. | PRQR | Chief Executive Officer | Officer | $261.0K | Open filing |
| 2026-07-08 | ProQR Therapeutics N.V. | PRQR | Chief Executive Officer | Officer | $238.5K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ $100k
- 3/3
- Cluster buying · 15D
- 3/3
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.